First Successful Aortic Valve Implantation with the CoreValve <i>ReValving</i><sup>™</sup> System via Right Subclavian Artery Access: A Case Report
DOI:
https://doi.org/10.1532/HSF98.20081021Abstract
We successfully implanted a bioprosthetic aortic valve via the right subclavian artery within the framework of the CoreValve transapical aortic valve replacement (TAVR) ReValving™ (CoreValve, Irvine, CA, USA) clinical trial on November 20, 2007, at the Clinic for Cardiovascular Surgery at the German Heart Center Munich, Technical University Munich. The self-expanding aortic valve prosthesis is primarily designed for retrograde delivery across the aortic valve. The described approach via the right subclavian artery was performed because of severe peripheral vascular disease of the femoral and iliac arteries, as well as the left subclavian artery, and because a transapical delivery system was not available at the time of surgery.References
Cribier A, Eltchaninoff H, Bash A, et al. 2002. Percutaneous transcatheter implantation of an aortic valve prosthesis for calcific aortic stenosis: first human case description. Circulation106:3006-8.nGrube E, Schuler G, Buellesfeld L, et al. 2007. Percutaneous aortic valve replacement for severe aortic stenosis in high-risk patients using the second- and current third-generation self-expanding CoreValve prosthesis: device success and 30-day clinical outcome. J Am Coll Cardiol50:69-76.nIung B, Cachier A, Baron G, et al. 2005. Decision-making in elderly patients with severe aortic stenosis: why are so many denied surgery? Eur Heart J26:2714-20.nLange R, Schreiber C, et al. 2006. First successful transapical aortic valve implantation with the CoreValve Revalving™ system: a case report. Heart Surg Forum10:E478-9.nNashef SA, Roques F, Michel P, Gauducheau E, Lemeshow S, Salamon R., and the EuroSCORE Study Group. 1999. European system for cardiac operative risk evaluation (EuroSCORE). Eur J Cardiothorac Surg16:9-13.n
